Drug intelligence / Profile preview

Weibing II

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Weibing II is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University. It is one of four syndrome-differentiated formulae (Weibing I–IV) evaluated for the treatment of functional dyspepsia. The therapeutic strategy utilizes TCM syndrome differentiation, specifically focusing on the balance between cold and heat, and asthenia (deficiency) and sthenia (excess). Weibing II is intended to address a specific pathological pattern within this framework to improve gastric motility and alleviate dyspeptic symptoms.

Beyond the preview

Go deeper on Weibing II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weibing II.

Explore the full profile